Triptorelin (Trelstar, Triptodur)

A GnRH agonist approved for prostate cancer and early puberty, and also used in IVF.

Evidence: Extensive clinical research
Half-life: Varies
Sources: 3 cited

Is triptorelin FDA-approved?

FDA-approved as Trelstar (prostate cancer) and Triptodur (precocious puberty).

Overview

Triptorelin is a stronger, longer-lasting form of GnRH. Given continuously as a depot shot, it first causes a surge of LH and testosterone, then shuts the system down, which is how it treats prostate cancer and early puberty.

How it works

It binds GnRH receptors much more tightly than natural GnRH. A short exposure triggers LH and FSH release; continuous exposure makes the receptors stop responding.

How long does triptorelin stay in the body?

A few hours after a standard shot; depot forms release it over 1–6 months.

What it's studied for

Prostate cancer
Central precocious puberty
Breast cancer (ovarian suppression)
Endometriosis and IVF

Reported side effects

Hot flashes
Temporary flare of symptoms at the start of depot treatment
Bone loss with long-term suppression

Sources

The studies and prescribing labels this page is written from.